An Automated, Online Feasibility Randomized Controlled Trial of a Just-In-Time Adaptive Intervention for Smoking Cessation (Quit Sense).
Journal
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751
Informations de publication
Date de publication:
09 Jun 2023
09 Jun 2023
Historique:
received:
02
12
2022
revised:
02
02
2023
accepted:
01
03
2023
medline:
12
6
2023
pubmed:
14
4
2023
entrez:
13
4
2023
Statut:
ppublish
Résumé
Learned smoking cues from a smoker's environment are a major cause of lapse and relapse. Quit Sense, a theory-guided Just-In-Time Adaptive Intervention smartphone app, aims to help smokers learn about their situational smoking cues and provide in-the-moment support to help manage these when quitting. A two-arm feasibility randomized controlled trial (N = 209) to estimate parameters to inform a definitive evaluation. Smoker's willing to make a quit attempt were recruited using online paid-for adverts and randomized to "usual care" (text message referral to NHS SmokeFree website) or "usual care" plus a text message invitation to install Quit Sense. Procedures, excluding manual follow-up for nonresponders, were automated. Follow-up at 6 weeks and 6 months included feasibility, intervention engagement, smoking-related, and economic outcomes. Abstinence was verified using cotinine assessment from posted saliva samples. Self-reported smoking outcome completion rates at 6 months were 77% (95% CI 71%, 82%), viable saliva sample return rate was 39% (95% CI 24%, 54%), and health economic data 70% (95% CI 64%, 77%). Among Quit Sense participants, 75% (95% CI 67%, 83%) installed the app and set a quit date and, of those, 51% engaged for more than one week. The 6-month biochemically verified sustained abstinence rate (anticipated primary outcome for definitive trial), was 11.5% (12/104) among Quit Sense participants and 2.9% (3/105) for usual care (adjusted odds ratio = 4.57, 95% CIs 1.23, 16.94). No evidence of between-group differences in hypothesized mechanisms of action was found. Evaluation feasibility was demonstrated alongside evidence supporting the effectiveness potential of Quit Sense. Running a primarily automated trial to initially evaluate Quit Sense was feasible, resulting in modest recruitment costs and researcher time, and high trial engagement. When invited, as part of trial participation, to install a smoking cessation app, most participants are likely to do so, and, for those using Quit Sense, an estimated one-half will engage with it for more than 1 week. Evidence that Quit Sense may increase verified abstinence at 6-month follow-up, relative to usual care, was generated, although low saliva return rates to verify smoking status contributed to considerable imprecision in the effect size estimate.
Identifiants
pubmed: 37055073
pii: 7116281
doi: 10.1093/ntr/ntad032
pmc: PMC10256891
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1319-1329Subventions
Organisme : NIHR
Organisme : Public Health Research Programme
ID : 17/92/31
Organisme : Department of Health and Social Care
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.
Références
Ecancermedicalscience. 2016 Jun 07;10:ed56
pubmed: 27350794
Psychopharmacology (Berl). 2004 Dec;177(1-2):195-9
pubmed: 15179542
BMJ Open. 2021 Apr 26;11(4):e048204
pubmed: 33903144
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Cochrane Database Syst Rev. 2017 Sep 04;9:CD007078
pubmed: 28869775
Res Nurs Health. 2006 Dec;29(6):533-42
pubmed: 17131277
Nicotine Tob Res. 2020 Jun 12;22(7):1086-1097
pubmed: 31570931
J Epidemiol Community Health. 1998 May;52(5):318-23
pubmed: 9764283
Nicotine Tob Res. 2019 Jan 4;21(2):234-240
pubmed: 29220524
Trials. 2014 Jul 03;15:264
pubmed: 24993581
Nicotine Tob Res. 2019 Jan 4;21(2):241-248
pubmed: 29370401
Health Psychol. 2011 Sep;30(5):588-96
pubmed: 21574708
JMIR Res Protoc. 2016 Aug 10;5(3):e161
pubmed: 27511829
Addiction. 2005 Mar;100(3):299-303
pubmed: 15733243
Addict Behav. 2011 Apr;36(4):315-9
pubmed: 21215528
J Health Psychol. 2015 Nov;20(11):1427-33
pubmed: 24296735
Lancet Respir Med. 2014 Dec;2(12):997-1006
pubmed: 25262458
JAMA. 1994 Feb 23;271(8):589-94
pubmed: 8301790
BMC Public Health. 2017 Nov 21;17(1):890
pubmed: 29162043
Nicotine Tob Res. 2013 Jan;15(1):77-82
pubmed: 22523120
NPJ Digit Med. 2020 Mar 12;3:35
pubmed: 32195370
J Med Internet Res. 2019 Nov 12;21(11):e14911
pubmed: 31714253
Addiction. 2014 Jul;109(7):1184-93
pubmed: 24661312
Nicotine Tob Res. 2011 Feb;13(2):94-102
pubmed: 21147894
Addiction. 2022 Apr;117(4):1079-1094
pubmed: 34636086
Nicotine Tob Res. 2016 May 28;19(3):379-383
pubmed: 27235703
J Consult Clin Psychol. 1996 Apr;64(2):366-79
pubmed: 8871421
Ann Behav Med. 2018 May 18;52(6):446-462
pubmed: 27663578
Addiction. 2022 May;117(5):1220-1241
pubmed: 34514668
J Med Internet Res. 2020 Mar 9;22(3):e16907
pubmed: 32149716
BMJ Open. 2018 Jan 21;8(1):e017105
pubmed: 29358418
Addiction. 2012 Dec;107(12):2183-90
pubmed: 22690882
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Ann Behav Med. 2013 Aug;46(1):81-95
pubmed: 23512568
Addict Behav. 2013 Jun;38(6):2224-9
pubmed: 23501139
J Subst Abuse Treat. 2009 Apr;36(3):235-43
pubmed: 18715743
JAMA Intern Med. 2020 Nov 1;180(11):1472-1480
pubmed: 32955554
JMIR Mhealth Uhealth. 2016 Sep 16;4(3):e106
pubmed: 27637405
Nicotine Tob Res. 2012 May;14(5):569-77
pubmed: 22311960
Nicotine Tob Res. 2013 Nov;15(11):1883-91
pubmed: 23780705
Addict Behav. 2021 Jan;112:106616
pubmed: 32932102
Addiction. 2011 Mar;106(3):631-8
pubmed: 21134020
J Med Internet Res. 2018 Aug 24;20(8):e10351
pubmed: 30143479
Nicotine Tob Res. 2010 May;12(5):489-99
pubmed: 20231242
Lancet. 2021 Jun 19;397(10292):2337-2360
pubmed: 34051883
Cochrane Database Syst Rev. 2019 Oct 22;10:CD006611
pubmed: 31638271
JMIR Mhealth Uhealth. 2017 Apr 25;5(4):e56
pubmed: 28442453